Niagen Bioscience (NAGE) Asset Utilization Ratio (2011 - 2026)
Niagen Bioscience (NAGE) reported Asset Utilization Ratio of 1.18 for Q1 2026, down 18.09% year-over-year from 1.44 in Q1 2025, and down 6.62% quarter-over-quarter from 1.27 in Q4 2025.
Niagen Bioscience (NAGE) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 14 years of Asset Utilization Ratio data on file, last reported at 1.18 in Q1 2026.
- Asset Utilization Ratio for Q1 2026 came in at 1.18, down 18.09% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.18 (down 18.09% YoY), and the FY2025 annual result was 1.48, down 8.32% from the prior year.
- Asset Utilization Ratio fell to 1.18 in Q1 2026 per NAGE's latest filing, from 1.27 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 1.66 in Q3 2024 and troughed at 1.18 in Q1 2026.
- A 5-year average of 1.44 and a median of 1.45 in 2022 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2022 and 2025: Asset Utilization Ratio soared 44.59% in 2022, then decreased 20.72% in 2025.
- A 5-year view of Asset Utilization Ratio shows it stood at 1.45 in 2022, then rose by 6.66% to 1.54 in 2023, then climbed by 3.56% to 1.6 in 2024, then fell by 20.72% to 1.27 in 2025, then declined by 6.62% to 1.18 in 2026.
- Business Quant data shows NAGE's Asset Utilization Ratio at 1.18 in Q1 2026, 1.27 in Q4 2025, and 1.32 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 0.55 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 0.60 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 1,422.00 |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn | 1.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.18 |
| Dec 31, 2025 | 1.27 |
| Sep 30, 2025 | 1.32 |
| Jun 30, 2025 | 1.35 |
| Mar 31, 2025 | 1.44 |
| Dec 31, 2024 | 1.60 |
| Sep 30, 2024 | 1.66 |
| Jun 30, 2024 | 1.58 |
| Mar 31, 2024 | 1.53 |
| Dec 31, 2023 | 1.54 |
| Sep 30, 2023 | 1.56 |
| Jun 30, 2023 | 1.51 |
| Mar 31, 2023 | 1.43 |
| Dec 31, 2022 | 1.45 |
| Sep 30, 2022 | 1.49 |
| Jun 30, 2022 | 1.39 |
| Mar 31, 2022 | 1.26 |
| Dec 31, 2021 | 1.14 |
| Sep 30, 2021 | 1.03 |
| Jun 30, 2020 | 1.41 |